Lupin unveils first generic version of Oracea in US

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-10 05:45 GMT   |   Update On 2024-04-10 05:45 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced the launch of first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Read also: Lupin gets USFDA nod for generic equivalent of Oracea Capsules

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

Advertisement

Rosacea is a chronic skin condition characterized by facial redness, visible blood vessels, and sometimes small, red, pus-filled bumps. It typically affects the central part of the face and can also involve eye irritation. While the exact cause is unknown, factors like genetics, blood vessel abnormalities, and certain bacteria may contribute. 

Doxycycline Capsules had estimated annual sales of USD 128 million in the U.S. (IQVIA MAT February 2024).

Read also: Lupin bags USFDA nod for Eslicarbazepine Acetate Tablets for partial-onset seizures

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin names Dr Ranjana Pathak as Chief Quality Officer

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News